Zentalis Pharmaceuticals
ZNTL
117 hedge funds and large institutions have $64.5M invested in Zentalis Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 34 increasing their positions, 44 reducing their positions, and 37 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4.12% less ownership
Funds ownership: 81.4% → 77.28% (-4.1%)
11% less funds holding
Funds holding: 132 → 117 (-15)
23% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 44
31% less capital invested
Capital invested by funds: $92.9M → $64.5M (-$28.4M)
41% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 37
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $73K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.28M |
| 2 |
Renaissance Technologies
New York
|
+$928K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$780K |
| 4 |
Two Sigma Investments
New York
|
+$717K |
| 5 |
TCM
Tybourne Capital Management
Hong Kong
|
+$681K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.28M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.38M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$973K |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$940K |
| 5 |
DC
Decheng Capital
Menlo Park,
California
|
-$919K |
ZNTL Hedge Fund Activity: Q2 2025 in Review
117 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q2 2025, worth a combined $64.5M — down 31% from $92.9M a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of ZNTL and 22 opened new positions — a net loss of 15 holders — while 44 trimmed existing stakes and 34 added.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $1.28M. The largest seller was BlackRock, cutting an estimated $3.28M.
- 117 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q2 2025, down from 132 in Q1 2025.
- Funds reported $64.5M of Zentalis Pharmaceuticals stock for Q2 2025, down 31% quarter-over-quarter.
- 22 funds opened new Zentalis Pharmaceuticals positions in Q2 2025 and 37 closed out, a net change of -15 holders.
- The largest Zentalis Pharmaceuticals buyer in Q2 2025 was Balyasny Asset Management, an estimated $1.28M added.
- The largest Zentalis Pharmaceuticals seller in Q2 2025 was BlackRock, an estimated $3.28M sold.
Based on aggregated 13F filings for Q2 2025.